Elusys’ HP Antibody technology to be used to find full product profile of ETI-211.
Elusys Therapeutics and Pfizer will work together to develop new therapeutics for select infectious diseases using Elusys’ HP Antibody™ technology. The exclusive collaborative research and license agreement includes ETI-211, an HP Antibody for the treatment of methicillin-resistant Staphylococcus aureus infections.
Under the terms of the agreement, Elusys and Pfizer will determine the full product profile of ETI-211 and perform research on other indications of the HP Antibody technology. Elusys will receive an upfront equity investment, research and development funding, and near-term research milestones.
Elusys granted Pfizer the option to acquire an exclusive worldwide license to products developed under the agreement. If Pfizer exercises this option, Elusys will receive clinical and sales milestones, as well as royalties on sales of products.
HP Antibodies enhance the effectiveness of the body’s natural defense mechanisms to remove and destroy life threatening pathogens. An HP Antibody drug consists of a Mab specific to an immune receptor (CR1) that is chemically linked to a second antibody that binds a particular pathogen. By targeting CR1, HP Antibodies enhance a natural clearance mechanism and direct the rapid removal of pathogens into liver macrophages, where they are destroyed and removed from the body.
